PolyNovo Limited (ASX:PNV)
Australia
· Delayed Price · Currency is AUD | Market Cap | 860.10M |
| Revenue (ttm) | 115.58M |
| Net Income (ttm) | 5.91M |
| Shares Out | 690.84M |
| EPS (ttm) | 0.01 |
| PE Ratio | 148.25 |
| Forward PE | 83.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,152,278 |
| Average Volume | 4,361,449 |
| Open | 1.300 |
| Previous Close | 1.280 |
| Day's Range | 1.235 - 1.300 |
| 52-Week Range | 1.125 - 2.780 |
| Beta | 1.73 |
| RSI | 36.61 |
| Earnings Date | May 23, 2025 |
About PolyNovo
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MT... [Read more]
Financial Performance
Financial StatementsNews
PolyNovo chief executive steps down after dispute with chairman
The burns treatment biotech has had a difficult year and now Swami Raote is leaving after a slump in the company’s share price and a brawl with the board.
David Williams says he makes no apologies for ‘aggressive’ style
The outspoken investment banker is the chairman of PolyNovo. The burns treatment company’s chief executive is leaving after a falling out with the board.
Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and ...
Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and Strategic Growth